- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging epigenetic-modulating therapies in lymphoma
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-03-05
DOI
10.1038/s41571-019-0190-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806
- (2018) Daniel O. Persky et al. AMERICAN JOURNAL OF HEMATOLOGY
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi
- (2018) Francesco Zaja et al. LEUKEMIA & LYMPHOMA
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
- (2018) Qi Lai et al. ONCOGENE
- The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
- (2018) A. Esteve-Arenys et al. ONCOGENE
- AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis
- (2018) Matt Teater et al. Nature Communications
- BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
- (2018) Hatice Gulcin Ozer et al. Cancer Discovery
- Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2
- (2018) Amir T. Fathi et al. JAMA Oncology
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
- (2018) Andrew M. Intlekofer et al. NATURE
- Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
- (2018) Michael Dickinson et al. BLOOD
- Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
- (2017) Vincent Ribrag et al. HAEMATOLOGICA
- INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS
- (2017) F. Morschhauser et al. HEMATOLOGICAL ONCOLOGY
- BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
- (2017) B Sun et al. LEUKEMIA
- The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis
- (2017) P Garrido Castro et al. LEUKEMIA
- Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen
- (2017) Michael Schaffer et al. LEUKEMIA & LYMPHOMA
- JQ1 reduces Epstein–Barr virus-associated lymphoproliferative disease in mice without sustained oncogene repression
- (2017) Amanda He et al. LEUKEMIA & LYMPHOMA
- Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma
- (2017) Bei Hu et al. LEUKEMIA & LYMPHOMA
- EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
- (2017) Dorothy Brach et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
- (2017) Andrea Piunti et al. NATURE MEDICINE
- Marked for death: targeting epigenetic changes in cancer
- (2017) Sophia Xiao Pfister et al. NATURE REVIEWS DRUG DISCOVERY
- Analysis of DNA methylation in single circulating tumor cells
- (2017) C F Pixberg et al. ONCOGENE
- Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma
- (2017) Elisa Oricchio et al. Science Translational Medicine
- EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop
- (2017) Wendy Béguelin et al. Nature Communications
- Identification of cell-type-specific mutations in nodal T-cell lymphomas
- (2017) T B Nguyen et al. Blood Cancer Journal
- PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
- (2017) Berkley E. Gryder et al. Cancer Discovery
- The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma
- (2017) Jiyuan Zhang et al. Cancer Discovery
- Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
- (2017) Vincent Ribrag et al. HAEMATOLOGICA
- Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
- (2016) S. E. Assouline et al. BLOOD
- Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome
- (2016) F. Child et al. BRITISH JOURNAL OF DERMATOLOGY
- Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma
- (2016) Yago Nieto et al. CANCER
- EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis
- (2016) Wendy Béguelin et al. CANCER CELL
- Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma
- (2016) Irina V. Tiper et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
- (2016) Yuhki Yokoyama et al. CANCER RESEARCH
- First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies
- (2016) S. Postel-Vinay et al. EUROPEAN JOURNAL OF CANCER
- ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
- (2016) C. L. Batlevi et al. HAEMATOLOGICA
- Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors
- (2016) Tatjana Maria Swerev et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520
- (2016) Soham D. Puvvada et al. LEUKEMIA & LYMPHOMA
- BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
- (2016) S. J. Hogg et al. MOLECULAR CANCER THERAPEUTICS
- BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells
- (2016) S V Muralidharan et al. ONCOGENE
- The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development
- (2016) François Lemonnier et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
- (2016) Yanwen Jiang et al. Cancer Discovery
- The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
- (2016) Ramiro Vázquez et al. Oncotarget
- Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia
- (2016) Etienne Danis et al. Cell Reports
- Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma
- (2016) Colin Flinders et al. Genome Medicine
- Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance
- (2016) Michaël Van Damme et al. Clinical Epigenetics
- Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
- (2016) Benet Pera et al. Clinical Epigenetics
- ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
- (2016) C. L. Batlevi et al. HAEMATOLOGICA
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
- (2015) Y. Shi et al. ANNALS OF ONCOLOGY
- Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas
- (2015) Yago Nieto et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma
- (2015) C. Wang et al. BLOOD
- Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation
- (2015) L. Alinari et al. BLOOD
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL
- (2015) S. Rozati et al. CLINICAL CANCER RESEARCH
- Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis
- (2015) Marcela C. Robaina et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
- (2015) R. Chen et al. HAEMATOLOGICA
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
- (2015) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis
- (2015) Cheryl M. Koh et al. NATURE
- A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
- (2015) Elayne Chan-Penebre et al. Nature Chemical Biology
- Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis
- (2015) Jiyuan Zhang et al. NATURE MEDICINE
- The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development
- (2015) Ana Ortega-Molina et al. NATURE MEDICINE
- Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
- (2015) R Gopalakrishnan et al. ONCOGENE
- Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation
- (2015) Michael R. Green et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival
- (2015) Amanda Panfil et al. Viruses-Basel
- Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas
- (2015) M A Lunning et al. Blood Cancer Journal
- PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers
- (2015) Y. Li et al. Cancer Discovery
- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
- (2015) R. Chen et al. HAEMATOLOGICA
- Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial
- (2015) Daryl Tan et al. Lancet Haematology
- Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
- (2015) Jehan Dupuis et al. Lancet Haematology
- Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit” lymphoma with very poor outcome?
- (2015) Fazila Asmar et al. Oncotarget
- Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes
- (2014) N. Chambwe et al. BLOOD
- A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- (2014) Michinori Ogura et al. BRITISH JOURNAL OF HAEMATOLOGY
- Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker
- (2014) Manuela Giachelia et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Somatic RHOA mutation in angioimmunoblastic T cell lymphoma
- (2014) Mamiko Sakata-Yanagimoto et al. NATURE GENETICS
- EZH2 mutations are frequent and represent an early event in follicular lymphoma
- (2013) C. Bodor et al. BLOOD
- A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
- (2013) Lihua E. Budde et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia
- (2013) Leigh A. Humphries et al. BRITISH JOURNAL OF HAEMATOLOGY
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
- (2013) Y. Oki et al. CLINICAL CANCER RESEARCH
- Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma
- (2013) Kelly A. Cycon et al. IMMUNOLOGY
- Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
- (2013) Marieta Caganova et al. JOURNAL OF CLINICAL INVESTIGATION
- The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
- (2013) Jan M. Klein et al. PLoS One
- Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
- (2013) T. Clozel et al. Cancer Discovery
- Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
- (2013) C. C. Oakes et al. Cancer Discovery
- Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity
- (2013) Subhajyoti De et al. PLoS Genetics
- Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study
- (2012) Asifa Malik et al. Clinical Lymphoma Myeloma & Leukemia
- Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
- (2012) Madeleine Duvic et al. EUROPEAN JOURNAL OF CANCER
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma:in vitroand phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
- (2012) Reinhard Dummer et al. LEUKEMIA & LYMPHOMA
- Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells
- (2012) Stefanie Kewitz et al. LEUKEMIA RESEARCH
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
- (2012) Jinghui Zhang et al. NATURE
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
- (2012) Panagiotis Ntziachristos et al. NATURE MEDICINE
- Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia
- (2011) X.-J. Yan et al. BLOOD
- Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
- (2011) L. Kretzner et al. CANCER RESEARCH
- Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- (2011) Mark Kirschbaum et al. JOURNAL OF CLINICAL ONCOLOGY
- Inactivating mutations of acetyltransferase genes in B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- Analysis of the coding genome of diffuse large B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE GENETICS
- Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma
- (2010) V. V. Leshchenko et al. BLOOD
- DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma
- (2010) R. Shaknovich et al. BLOOD
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas
- (2010) Khaled Amara et al. CANCER SCIENCE
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started